At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 28 enrolled
Drug / intervention
LCZ696 +1 moredrug
Likely dose
LCZ696 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Three-period, Single Sequence Study to Evaluate the Pharmacokinetic Drug-drug Interaction Between LCZ696 and Sildenafil in Subjects With Mild to Moderate Hypertension
In Brief
A Phase 2 clinical trial evaluating LCZ696 and Sildenafil for Mild to Moderate Hypertension. Completed, enrolled 28 participants across 1 site.
Detailed Summary
This study was conducted to investigate the potential for a pharmacokinetic drug-drug interaction in support of the co-administration of LCZ696 and sildenafil.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMild to Moderate Hypertension
CountriesGermany
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 2012
Enrollment StartSep 2012
Primary CompletionJan 2013
TodayJul 2026
First PostedMay 18, 2012
Enrollment StartSep 1, 2012
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 14.1 years ago
Interventions
LCZ696drug
LCZ696 400mg QD was administered alone for 4 days and in combination with sildenafil for 1 day
Sildenafildrug
Sildenafil 50 mg single dose was administered alone for 1 days and in combination with LCZ696 400mg QD for 1 day